Candesartan prevented development of diabetes mellitus in heart failure

January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p11
Academic Journal
This article focuses on a study conducted to examine the efficacy of candesartan in preventing the development of diabetes mellitus in heart failure. 5436 patients with symptomatic heart failure who did not have diabetes at baseline came from 3 parallel trials. Candesartan reduced development of diabetes and a composite endpoint of diabetes and all-cause mortality more than placebo.


Related Articles

  • Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Gheorghiade, Mihai; Albaghdadi, Mazen; Zannad, Faiez; Fonarow, Gregg C.; B�hm, Michael; Gimpelewicz, Claudio; Botha, Jaco; Moores, Shelley; Lewis, Eldrin F.; Rattunde, Henning; Maggioni, Aldo // European Journal of Heart Failure;Jan2011, Vol. 13 Issue 1, p100 

    Background Hospitalizations for acute heart failure syndromes (AHFS) are associated with high post-discharge mortality and readmission rates in spite of available therapies. Renin�angiotensin�aldosterone system (RAAS) antagonists improve outcomes in outpatients with heart failure (HF)...

  • Effect of perioperative β blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. Juul, Anne Benedicte; Wetterslev, Jørn; Gluud, Christian; Kofoed-Enevoldsen, Allan; Jensen, Gorm; Callesen, Torben; Nørgaard, Peter; Fruergaard, Kim; Bestle, Morten; Vedelsdal, Rune; Miran, André; Jacobsen, Jon; Roed, Jakob; Mortensen, Maj-Britt; Jørgensen, Lise; Jørgensen, Jørgen; Rovsing, Marie-Louise; Petersen, Pernille Lykke; Pott, Frank; Haas, Merete // BMJ: British Medical Journal (International Edition);6/24/2006, Vol. 332 Issue 7556, p1482 

    Objectives To evaluate the long term effects of perioperative β blockade on mortality and cardiac morbidity in patients with diabetes undergoing major non-cardiac surgery. Design Randomised placebo controlled and blinded multicentre trial. Analyses were by intention to treat. Setting...

  • Ethics and eplerenone. Gupta, Shruti; Fugh-Berman, Adriane J.; Scialli, Anthony // Journal of Medical Ethics;Feb2013, Vol. 39 Issue 2, p110 

    The use of a placebo arm in clinical trials is unethical if there is an active comparator that is acceptably safe and effective. We argue that reasonable evidence of effectiveness and safety of an inexpensive alternative to an expensive therapy is sufficient to require that the inexpensive...

  • Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Deedwania, Prakash C.; Ahmed, Mustafa I.; Feller, Margaret A.; Aban, Inmaculada B.; Love, Thomas E.; Pitt, Bertram; Ahmed, Ali // European Journal of Heart Failure;May2011, Vol. 13 Issue 5, p551 

    Aims To determine independent associations of diabetes mellitus with outcomes in a propensity-matched cohort of patients with acute myocardial infarction (AMI) and systolic heart failure (HF). Methods and results In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and...

  • Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes. Dormandy, John; Bhattacharya, Mondira; de Bruyn, Anne-Ruth van Troostenburg // Drug Safety;2009, Vol. 32 Issue 3, p187 

    People with type 2 diabetes mellitus have an excess risk of macrovascular disease and a poorer prognosis. PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) was a landmark study of secondary cardiovascular disease (CVD) prevention in type 2 diabetes that suggested a...

  • Baseline demographics of the Valsartan Heart Failure Trial. Cohn, Jay N.; Tognoni, Gianni; Glazer, Robert; Spormann, Dirk // European Journal of Heart Failure;Dec2000, Vol. 2 Issue 4, p439 

    Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in...

  • COMMENTARY: Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. Isley, William L. // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p34 

    The article focuses on a study which reveals that pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. Although glycemic control generally has not been shown to reduce macrovascular...

  • ACE inhibitors can prevent diabetes and heart failure.  // GP: General Practitioner;3/24/2003, p17 

    According to the results of a trial the angiotensin converting enzyme (ACE) inhibitors could prevent heart failure (HF) among patients at high risk of cardiovascular events. The ‘Heart Outcomes Prevention Evaluation’ (HOPE) study found ramipril cut the development rate of HF among...

  • Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE ... Krum, Henry; Massie, Barry; Abraham, William T.; Dickstein, Kenneth; Kober, Lars; McMurray, John J.V.; Desai, Ashkay; Gimpelewicz, Claudio; Kandra, Albert; Reimund, Bernard; Rattunde, Henning; Armbrecht, Juergen // European Journal of Heart Failure;Jan2011, Vol. 13 Issue 1, p107 

    Aims The renin�angiotensin�aldosterone system (RAAS) represents a key therapeutic target in heart failure (HF) management. However, conventional agents that block this system induce a reflex increase in plasma renin activity (PRA), which may lead to RAAS �escape'. Direct renin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics